Recombinant interleukin-2 treatment in patients with metastatic colorectal cancer: Effect on natural cytotoxicity

K. G. M. Park; S. D. Heys; J. B. Murray; P. D. Hayes; J. A. Ashby; C. R. Franks; O. Eremin

doi:10.1007/BF01741055

Recombinant interleukin-2 treatment in patients with metastatic colorectal cancer: Effect on natural cytotoxicity

K. G. M. Park, S. D. Heys, J. B. Murray, P. D. Hayes, J. A. Ashby, C. R. Franks, O. Eremin

Applied Medicine

Research output: Contribution to journal › Article › peer-review

7 Citations (Scopus)

Abstract

Natural cytotoxicity (natural killer, NK, and lymphokine-activated killer, LAK, activity) was documented in 12 patients with metastatic colorectal cancer, both before and after a 5-day course of continuous therapy with intravenous recombinant interleukin-2 (rIL-2). Treatment induced a substantial increase in circulating CD56⁺ lymphocytes (pretreatment: 12.1±6.9%, mean ± SD; posttreatment: 39.2±6.9%. Maximal NK cell activity was induced by treatment with rIL-2 but only suboptimal augmentation of LAK cell cytotoxicity was obtained. This study indicates that although continuous infusion of rIL-2 does have a significant effect on natural cytotoxicity, this is suboptimal and further studies are necessary to define the most efficacious immunity-enhancing regimens of therapy, thereby hopefully improving clinical outcome of rIL-2 treatment.

Original language	English
Pages (from-to)	53-58
Number of pages	6
Journal	Cancer Immunology Immunotherapy
Volume	35
Issue number	1
DOIs	https://doi.org/10.1007/BF01741055
Publication status	Published - Jan 1992

Keywords

Colorectal cancer
Cytotoxicity
Interleukin-2
Natural cytotoxicity

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/BF01741055Licence: Unspecified

Cite this

@article{a823af04e0d4454fbbd15b96b866a750,

title = "Recombinant interleukin-2 treatment in patients with metastatic colorectal cancer: Effect on natural cytotoxicity",

abstract = "Natural cytotoxicity (natural killer, NK, and lymphokine-activated killer, LAK, activity) was documented in 12 patients with metastatic colorectal cancer, both before and after a 5-day course of continuous therapy with intravenous recombinant interleukin-2 (rIL-2). Treatment induced a substantial increase in circulating CD56+ lymphocytes (pretreatment: 12.1±6.9%, mean ± SD; posttreatment: 39.2±6.9%. Maximal NK cell activity was induced by treatment with rIL-2 but only suboptimal augmentation of LAK cell cytotoxicity was obtained. This study indicates that although continuous infusion of rIL-2 does have a significant effect on natural cytotoxicity, this is suboptimal and further studies are necessary to define the most efficacious immunity-enhancing regimens of therapy, thereby hopefully improving clinical outcome of rIL-2 treatment.",

keywords = "Colorectal cancer, Cytotoxicity, Interleukin-2, Natural cytotoxicity",

author = "Park, {K. G. M.} and Heys, {S. D.} and Murray, {J. B.} and Hayes, {P. D.} and Ashby, {J. A.} and Franks, {C. R.} and O. Eremin",

year = "1992",

month = jan,

doi = "10.1007/BF01741055",

language = "English",

volume = "35",

pages = "53--58",

journal = "Cancer Immunology Immunotherapy",

issn = "0340-7004",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "1",

}

TY - JOUR

T1 - Recombinant interleukin-2 treatment in patients with metastatic colorectal cancer

T2 - Effect on natural cytotoxicity

AU - Park, K. G. M.

AU - Heys, S. D.

AU - Murray, J. B.

AU - Hayes, P. D.

AU - Ashby, J. A.

AU - Franks, C. R.

AU - Eremin, O.

PY - 1992/1

Y1 - 1992/1

N2 - Natural cytotoxicity (natural killer, NK, and lymphokine-activated killer, LAK, activity) was documented in 12 patients with metastatic colorectal cancer, both before and after a 5-day course of continuous therapy with intravenous recombinant interleukin-2 (rIL-2). Treatment induced a substantial increase in circulating CD56+ lymphocytes (pretreatment: 12.1±6.9%, mean ± SD; posttreatment: 39.2±6.9%. Maximal NK cell activity was induced by treatment with rIL-2 but only suboptimal augmentation of LAK cell cytotoxicity was obtained. This study indicates that although continuous infusion of rIL-2 does have a significant effect on natural cytotoxicity, this is suboptimal and further studies are necessary to define the most efficacious immunity-enhancing regimens of therapy, thereby hopefully improving clinical outcome of rIL-2 treatment.

AB - Natural cytotoxicity (natural killer, NK, and lymphokine-activated killer, LAK, activity) was documented in 12 patients with metastatic colorectal cancer, both before and after a 5-day course of continuous therapy with intravenous recombinant interleukin-2 (rIL-2). Treatment induced a substantial increase in circulating CD56+ lymphocytes (pretreatment: 12.1±6.9%, mean ± SD; posttreatment: 39.2±6.9%. Maximal NK cell activity was induced by treatment with rIL-2 but only suboptimal augmentation of LAK cell cytotoxicity was obtained. This study indicates that although continuous infusion of rIL-2 does have a significant effect on natural cytotoxicity, this is suboptimal and further studies are necessary to define the most efficacious immunity-enhancing regimens of therapy, thereby hopefully improving clinical outcome of rIL-2 treatment.

KW - Colorectal cancer

KW - Cytotoxicity

KW - Interleukin-2

KW - Natural cytotoxicity

UR - http://www.scopus.com/inward/record.url?scp=0026532440&partnerID=8YFLogxK

U2 - 10.1007/BF01741055

DO - 10.1007/BF01741055

M3 - Article

C2 - 1611623

AN - SCOPUS:0026532440

VL - 35

SP - 53

EP - 58

JO - Cancer Immunology Immunotherapy

JF - Cancer Immunology Immunotherapy

SN - 0340-7004

IS - 1

ER -

Recombinant interleukin-2 treatment in patients with metastatic colorectal cancer: Effect on natural cytotoxicity

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this